Why Did Metsera Stock Surge 15% On The Worst Trading Day Of 2025? Here's What Has Happened Since Its Listing
The newly listed clinical-stage biotechnology company, Metsera Inc. rose 15.01% on Monday as the broader markets declined.
Metsera, Inc. (MTSR): Among Stocks With At Least $10 Million In Insider Spending Recently
We recently published a list of 10 Stocks With At Least $10 Million In Insider Spending Recently. In this article, we are ...
Is Amneal Pharmaceuticals, Inc. (AMRX) the Best Weight Loss Drug Stock to Buy According to Analysts?
We recently published a list of 10 Best Weight Loss Drug Stocks to Buy According to Analysts. In this article, we are going ...
CenExel Research: CenExel Supports Metsera, Inc. in Successful Phase II Trial of MET-097 for Obesity and Metabolic Diseases
SALT LAKE CITY, UTAH / ACCESS Newswire / February 27, 2025 / CenExel is pleased to announce its partnership with Metsera, Inc., a clinical-stage biopharmaceutical company dedicated to advancing treatm ...
BioSpace4d
Kallyope Discreetly Drops Disappointing Data for Oral Obesity Candidate
While Kallyope’s drugs are mechanistically unique, the biotech is competing in a crowded space, with other therapies that ...
Is Amneal Pharmaceuticals, Inc. (AMRX) the Best Low Price Pharma Stock to Invest In Right Now?
We recently compiled a list of the 12 Best Low Price Pharma Stocks To Invest In Right Now. In this article, we are going to ...
manilatimes5d
Fury Gold Mines Limited to Acquire Quebec Precious Metals Corporation
Fury Gold Mines Limited (TSX: FURY, NYSE American: FURY) ('Fury”) and Quebec Precious Metals Corporation (TSXV: QPM, FSE: YXEP, OTC-BB: CJCFF) ('QPM”)  are pleased to announce that they have entered ...
Metsera to Present at TD Cowen’s 45th Annual Health Care Conference
Metsera, Inc. (Nasdaq: MTSR) (“Metsera” or the “Company”), a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases, today announced ...
Metsera: Capturing Of Obesity Market With Long-Acting GLP-1 Differentiation
Metsera's IPO raised $316.2 million, funding its obesity drug MET-097i, which shows promise with once-monthly dosing. Read ...
Metsera started by Guggenheim at buy on obesity drug opportunity
Guggenheim has initiated coverage of Metsera (MTSR) with a buy rating, citing the company's obesity drug candidates. Read ...
Why this newly public biotech could become a force in obesity treatments
Metsera’s GLP-1 peptide has a long half-life, meaning it could be administered once a month. The company is ready to scale up ...
Investing6d
Wall Street bullish on Metsera following January IPO on obesity drug pipeline
Investing.com -- Wall Street analysts initiated coverage on Metsera with bullish outlook given the biotech firm’s ...